|Summary sheet: 4-HO-DET|
|Common names||4-HO-DET, Ethocin, CZ-74|
|Routes of Administration|
4-Hydroxy-N,N-diethyltryptamine (also known as 4-HO-DET, CZ-74, and Ethocin) is a lesser-known synthetic psychedelic of the tryptamine chemical class that produces psilocin-like psychedelic effects when adminstered. 4-HO-DET is a close structural and functional analog of psilocin (4-HO-DMT), the principal psychoactive component in magic mushrooms. It is notable for sharing many of its core features while retaining subtle variations in its duration, visual, cognitive and bodily effects.
This compound was first discovered in the late 1950s by Albert Hofmann and Franz Troxler in their investigation of various psychedelic compounds that were structurally and chemically related to the principle active components he isolated from magic mushrooms, psilocybin (4-PO-DMT) and psilocin (4-HO-DMT). The substance was used together with its phosphoryloxy-analog 4-PO-DET in human clinical trials in the 1960s by the German researchers Hanscarl Leuner and G. Baer.
Since its inception, 4-HO-DET has remained relatively uncommon and has very little documentation of human usage, with the majority of psychedelic users preferring more traditional psychedelics like the psilocybin and psilocin in psilocybin mushrooms, or more recently, 4-AcO-DMT. Today, it is either used as a recreational substance or an entheogen, has no documentation of being sold on the streets and is primarily acquired through the use of online research chemical vendors.
4-HO-DET, or 4-hydroxy-N,N-diethyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine chemical class. Tryptamines share a core structure comprised of a bicyclic indole heterocycle attached at R3 to an amino group via an ethyl side chain. 4-HO-DET is substituted at R4 of its indole heterocycle with a hydroxyl functional group OH−. It also contains two ethyl chains bound to the terminal amine RN of its tryptamine backbone (DET).
However, the role of these interactions and how they result in the psychedelic experience continues to remain an object of scientific elucidation.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
In comparison to other isolated synthetic tryptamine compounds such as 4-AcO-DMT and 4-HO-DMT, 4-HO-DET has been reported as being similar in terms of its visual, cognitive and physical effects, albeit with a slightly longer duration, less in the way of bodily effects, and more "synthetic" or "algorithmic"-style visuals.
Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Spontaneous physical sensations
- Tactile enhancement
- Temperature regulation suppression
- Bodily control enhancement
- Increased heart rate
- Excessive yawning - This effect seems to be uniquely pronounced among psilocin and related tryptamines. It can occur to a lesser degree on LSD and very rarely on psychedelic phenethylamines like mescaline. It typically occurs in combination with watery eyes. However, many anecdotal reports suggest that this component is not as noticeable compared to the aforementioned psychedelics
- Watery eyes
- Frequent urination
- Muscle contractions
- Olfactory hallucination
- Pupil dilation
- Runny nose
- Drifting (melting, breathing, morphing and flowing)
- Colour tinting
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of psilocin, ayahuasca and 2C-T-7 than LSD or 2C-B. It can be comprehensively described through its variations as intricate in complexity, abstract in form, mostly synthetic in style, unstructured in organization, dimly lit and monotone in scheme, glossy in shading, sharp in edges, large in size, slow in speed, smooth in motion, equally rounded and angular in corners, non-immersive in-depth and consistent in intensity. They have a notably "synthetic" feel to them and at higher dosages are significantly more likely to result in states of Level 8B visual geometry over Level 8A.
- The cognitive effects of 4-HO-DET can be described as mildly more stimulating and lucid in style when compared to other similar psychedelics such as psilocybin or 2C-C which tend to be more sedating. It has also been characterized as possessing a more "neutral", "analytical" headspace with minimal memory disruptions or emotional confusion compared to psilocybin mushrooms. The most prominent of these typical effects generally include:
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 4-HO-DET use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 4-HO-DET is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 4-HO-DET suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
4-HO-DET is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 4-HO-DET are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 4-HO-DET presents cross-tolerance with all psychedelics, meaning that after the consumption of 4-HO-DET all psychedelics will have a reduced effect.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed in the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
- Stimulants (Amphetamine, cocaine, methylphenidate, ...) - Stimulants affect many parts of the brain and alter dopaminergic function. Combined with psychedelics, stimulation can turn into severe anxiety, panic, thought loops, and paranoia. This interaction may result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures in susceptible individuals.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Germany: 4-HO-DET is controlled under Anlage I BtMG (Narcotics Act, Schedule I), former: Opiumgesetz (Opium Act) as of February 25, 1967. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
- Sweden: 4-HO-DET is classified as a health hazard under the Act on the Prohibition of Certain Goods Dangerous to Health as of November 1, 2005 in the regulation SFS 2005:733, making it illegal to sell or possess.
- United Kingdom: 4-HO-DET is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: 4-HO-DET is unscheduled in the United States. It may be considered an analogue of psilocin (4-HO-DMT) which is a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Therapeutic indoles for psychic stimulation and relief of mental depression | http://www.google.com/patents/US3072530
- United States Patent Office | https://www.erowid.org/archive/rhodium/pdf/psilocin.esters.pdf
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- "Vierte Verordnung über die den Betäubungsmitteln gleichgestellten Stoffe" (in German). Bundesanzeiger Verlag. Retrieved December 10, 2019.
- "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 10, 2019.
- Svensk författningssamling | http://www.notisum.se/rnp/sls/sfs/20050733.pdf
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e